The
Oncologist Newsletter appeared in my in-box this morning. Whilst not of
immediate relevance to my daily round, it is always good to have a refresher on
some of the background stuff…
 |
Practice-Changing Article
Currently, there are no uniform treatment lines for advanced chondrosarcoma patients, which results in a very diverse group of treatment regimens being used. In this study, the data of 112 patients was collected. It was concluded that some treatment regimens seem to have a better progression‐free survival compared with others, and that these results also differ between the chondrosarcoma subtypes. Prospective studies need to be conducted based on preclinical work to develop a uniform regimen to treat advanced chondrosarcoma patients according to the diagnosed histological subtype to improve their survival.
|
Review Article
This article highlights the importance of monitoring for immune‐mediated adverse events (IMAEs) in patients with Hodgkin lymphoma (HL) who receive anti‐programmed death‐1 (anti‐PD‐1) therapy, with particular attention given to the recognition and management of such events. The risk of individual IMAEs differs between patients with HL and those with solid tumors, as prior treatments may predispose certain organ systems to specific IMAEs. Accurate and prompt diagnosis of IMAEs is essential for optimal management, allowing PD‐1 inhibitor therapy to be restarted in order to maintain disease control. Potential difficulties, such as distinguishing disease progression from pneumonitis, or colitis from diarrhea, are highlighted to raise clinical awareness.
|
| |
|
|
|
Lessons Learned
> The combination of the antiangiogenic agent ziv‐aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested.
> Studies such as these emphasize the importance of considering overlapping toxicities when designing novel treatment combination regimens.
|
| |
|
|
|
Treatment for cancer may lead to development of cognitive difficulties in cancer survivors. This study aimed to evaluate a long-term cognitive functioning (CogF) in germ-cell tumor (GCT) survivors.
|
High-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma. However, elderly patients are often not considered ASCT candidates based on age alone. A retrospective analysis of patients ≥ 70 years of age with a diagnosis of Hodgkin or non-Hodgkin lymphoma receiving ASCT between 2000 and 2016 at two partner institutions was performed.
|
|
|
|
No comments:
Post a Comment